Paper32420063
EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib.
Buder A and 4 others. Transl Lung Cancer Res, 2020. Cited by 27 papers, by iCite.
Cite this record
ConductScience Library. EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib. Papers, record 32420063. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32420063
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References12
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30922878 | Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. | Lancet Respir Med | 2019 | https://conductscience.org/library/papers/30922878 | PubMed |
| 2 | 27055085 | Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. | JAMA Oncol | 2016 | https://conductscience.org/library/papers/27055085 | PubMed |
| 3 | 26730486 | The potential of liquid biopsies. | Curr Opin Oncol | 2016 | https://conductscience.org/library/papers/26730486 | PubMed |
| 4 | 30810887 | EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR. | Target Oncol | 2019 | https://conductscience.org/library/papers/30810887 | PubMed |
| 5 | 31411950 | Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. | J Clin Oncol | 2020 | https://conductscience.org/library/papers/31411950 | PubMed |
| 6 | 24429876 | Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/24429876 | PubMed |
| 7 | 27959700 | Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. | N Engl J Med | 2017 | https://conductscience.org/library/papers/27959700 | PubMed |
| 8 | 25829397 | Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/25829397 | PubMed |
| 9 | 29151359 | Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29151359 | PubMed |
| 10 | 30539501 | Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib. | Target Oncol | 2019 | https://conductscience.org/library/papers/30539501 | PubMed |
| 11 | 29505901 | Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC. | J Thorac Oncol | 2018 | https://conductscience.org/library/papers/29505901 | PubMed |
| 12 | 30397287 | The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response. | Br J Cancer | 2018 | https://conductscience.org/library/papers/30397287 | PubMed |
Cited by22
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41097693 | Artificial Intelligence-Enhanced Liquid Biopsy and Radiomics in Early-Stage Lung Cancer Detection: A Precision Oncology Paradigm. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41097693 | PubMed |
| 40825939 | The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis. | Biomark Med | 2025 | https://conductscience.org/library/papers/40825939 | PubMed |
| 39998904 | Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis. | Oncologist | 2025 | https://conductscience.org/library/papers/39998904 | PubMed |
| 38162173 | Brief Report: Droplet Digital Polymerase Chain Reaction Versus Plasma Next-Generation Sequencing in Detecting Clearance of Plasma EGFR Mutations and Carcinoembryonic Antigen Levels as a Surrogate Measure. | JTO Clin Res Rep | 2023 | https://conductscience.org/library/papers/38162173 | PubMed |
| 38012343 | Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib. | Sci Rep | 2023 | https://conductscience.org/library/papers/38012343 | PubMed |
| 37390764 | Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results. | ESMO Open | 2023 | https://conductscience.org/library/papers/37390764 | PubMed |
| 37240238 | Liquid Biopsy in Lung Cancer: Biomarkers for the Management of Recurrence and Metastasis. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37240238 | PubMed |
| 36969743 | Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells. | Cancer Res Commun | 2022 | https://conductscience.org/library/papers/36969743 | PubMed |
| 36928816 | A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. | Nat Med | 2023 | https://conductscience.org/library/papers/36928816 | PubMed |
| 36848029 | Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions. | Front Med | 2023 | https://conductscience.org/library/papers/36848029 | PubMed |
| 35713632 | Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403). | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35713632 | PubMed |
| 35004240 | EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome. | Transl Lung Cancer Res | 2021 | https://conductscience.org/library/papers/35004240 | PubMed |
| 34771566 | Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34771566 | PubMed |
| 34743498 | [Application Value of ctDNA-based MRD Dedection in Early Stage Non-small Cell Lung Cancer after Radical Surgery]. | Zhongguo Fei Ai Za Zhi | 2021 | https://conductscience.org/library/papers/34743498 | PubMed |
| 34527339 | Genomic alteration profiles of lung cancer and their relationship to clinical features and prognosis value using individualized genetic testing. | J Thorac Dis | 2021 | https://conductscience.org/library/papers/34527339 | PubMed |
| 34430591 | Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors. | Ann Transl Med | 2021 | https://conductscience.org/library/papers/34430591 | PubMed |
| 34427045 | EGFR-plasma mutations in prognosis for non-small cell lung cancer treated with EGFR TKIs: A meta-analysis. | Cancer Rep (Hoboken) | 2022 | https://conductscience.org/library/papers/34427045 | PubMed |
| 34073111 | Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34073111 | PubMed |
| 33919291 | Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients. | Biomolecules | 2021 | https://conductscience.org/library/papers/33919291 | PubMed |
| 33842353 | Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs. | Front Oncol | 2021 | https://conductscience.org/library/papers/33842353 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32420063
GET https://conductscience.org/api/papers/v1/32420063/cited_by?page=2